Protalix BioTherapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Protalix BioTherapeutics, Inc. (PLX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$7.45 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-06
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$7.45M.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$4.06M, a 122.96% decline year-over-year.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $13.54M.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$12.99M.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$13.36M.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$12.12M.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$13.09M, a 160.60% decline from fiscal 2015.
- Protalix BioTherapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $21.61M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$7.45M 10-Q · filed 2019-05-06 | -$11.51M derived: sum of 2 quarters · filed 2019-05-06 | $2.04M derived: sum of 3 quarters · filed 2019-05-06 | -$10.96M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-12-31 | -$4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $9.48M derived: sum of 2 quarters · filed 2019-03-18 | -$3.51M derived: sum of 3 quarters · filed 2019-03-18 | -$13.36M 10-K · filed 2019-03-18 |
| 2018-09-30 | $13.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18 | $549.00K derived: sum of 2 quarters · filed 2019-03-18 | -$9.29M 10-Q · filed 2019-03-18 | $8.39M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-06-30 | -$12.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-18 | -$22.84M 10-Q · filed 2019-03-18 | -$5.16M derived: sum of 3 quarters · filed 2019-05-06 | -$6.21M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-03-31 | -$9.84M 10-Q · filed 2019-05-06 | $7.84M derived: sum of 2 quarters · filed 2019-05-06 | $6.79M derived: sum of 3 quarters · filed 2019-05-06 | -$6.70M derived: sum of 4 quarters · filed 2019-05-06 |
| 2017-12-31 | $17.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $16.63M derived: sum of 2 quarters · filed 2019-03-18 | $3.15M derived: sum of 3 quarters · filed 2019-03-18 | -$12.12M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18 | -$14.54M derived: sum of 2 quarters · filed 2019-03-18 | -$29.80M 10-Q · filed 2019-03-18 | -$17.84M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | -$13.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-18 | -$28.75M 10-Q · filed 2019-03-18 | -$16.79M derived: sum of 3 quarters · filed 2019-03-18 | -$20.09M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | -$15.26M 10-Q · filed 2019-03-18 | -$3.30M derived: sum of 2 quarters · filed 2019-03-18 | -$6.61M derived: sum of 3 quarters · filed 2019-03-18 | -$18.65M derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | $11.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $8.65M derived: sum of 2 quarters · filed 2019-03-18 | -$3.39M derived: sum of 3 quarters · filed 2019-03-18 | -$13.09M 10-K · filed 2019-03-18 |
| 2016-09-30 | -$3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$15.35M derived: sum of 2 quarters · filed 2017-11-08 | -$25.05M 10-Q · filed 2017-11-08 | $17.07M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | -$12.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$21.75M 10-Q · filed 2017-08-09 | $20.38M derived: sum of 3 quarters · filed 2018-03-06 | $11.39M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | -$9.71M 10-Q · filed 2017-05-10 | $32.42M derived: sum of 2 quarters · filed 2018-03-06 | $23.43M derived: sum of 3 quarters · filed 2018-03-06 | $18.71M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | $42.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $33.14M derived: sum of 2 quarters · filed 2018-03-06 | $28.42M derived: sum of 3 quarters · filed 2018-03-06 | $21.61M 10-K · filed 2018-03-06 |
| 2015-09-30 | -$8.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$13.71M derived: sum of 2 quarters · filed 2016-11-09 | -$20.52M 10-Q · filed 2016-11-09 | -$26.07M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$11.53M 10-Q · filed 2016-08-08 | -$17.08M derived: sum of 3 quarters · filed 2017-03-16 | -$27.91M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$6.81M 10-Q · filed 2016-05-09 | -$12.36M derived: sum of 2 quarters · filed 2017-03-16 | -$23.19M derived: sum of 3 quarters · filed 2017-03-16 | -$29.73M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | -$5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$16.38M derived: sum of 2 quarters · filed 2017-03-16 | -$22.92M derived: sum of 3 quarters · filed 2017-03-16 | -$31.63M 10-K · filed 2017-03-16 |
| 2014-09-30 | -$10.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$17.37M derived: sum of 2 quarters · filed 2015-11-09 | -$26.08M 10-Q · filed 2015-11-09 | -$31.08M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | -$6.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$15.25M 10-Q · filed 2015-08-10 | -$20.25M derived: sum of 3 quarters · filed 2016-03-08 | $38.02M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | -$8.71M 10-Q · filed 2015-05-07 | -$13.71M derived: sum of 2 quarters · filed 2016-03-08 | $44.56M derived: sum of 3 quarters · filed 2016-03-08 | $35.82M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $53.27M derived: sum of 2 quarters · filed 2016-03-08 | $44.53M derived: sum of 3 quarters · filed 2016-03-08 | $34.36M 10-K · filed 2016-03-08 |
| 2013-09-30 | $58.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $49.53M derived: sum of 2 quarters · filed 2014-11-10 | $39.36M 10-Q · filed 2014-11-10 | $41.18M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | -$8.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$18.91M 10-Q · filed 2014-08-07 | -$17.09M derived: sum of 3 quarters · filed 2015-03-12 | -$26.15M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | -$10.16M 10-Q · filed 2014-05-08 | -$8.35M derived: sum of 2 quarters · filed 2015-03-12 | -$17.41M derived: sum of 3 quarters · filed 2015-03-12 | -$3.73M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$7.25M derived: sum of 2 quarters · filed 2015-03-12 | $6.43M derived: sum of 3 quarters · filed 2015-03-12 | $25.03M 10-K · filed 2015-03-12 |
| 2012-09-30 | -$9.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $4.61M derived: sum of 2 quarters · filed 2013-11-07 | $23.21M 10-Q · filed 2013-11-07 | $15.65M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-06-30 | $13.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $32.28M 10-Q · filed 2013-08-08 | $24.72M derived: sum of 3 quarters · filed 2014-03-13 | $15.23M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-03-31 | $18.60M 10-Q · filed 2013-05-09 | $11.04M derived: sum of 2 quarters · filed 2014-03-13 | $1.55M derived: sum of 3 quarters · filed 2014-03-13 | -$4.62M derived: sum of 4 quarters · filed 2014-03-13 |
| 2011-12-31 | -$7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | -$17.05M derived: sum of 2 quarters · filed 2014-03-13 | -$23.23M derived: sum of 3 quarters · filed 2014-03-13 | -$8.90M 10-K · filed 2014-03-13 |
| 2011-09-30 | -$9.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$15.66M derived: sum of 2 quarters · filed 2012-11-07 | -$1.34M 10-Q · filed 2012-11-07 | -$9.84M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | -$6.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $8.15M 10-Q · filed 2012-08-03 | -$347.00K derived: sum of 3 quarters · filed 2013-02-28 | -$10.91M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $14.33M 10-Q · filed 2012-05-09 | $5.83M derived: sum of 2 quarters · filed 2013-02-28 | -$4.73M derived: sum of 3 quarters · filed 2013-02-28 | |
| 2010-12-31 | -$8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$19.06M derived: sum of 2 quarters · filed 2013-02-28 | -$45.37M 10-K · filed 2013-02-28 | |
| 2010-09-30 | -$10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$36.87M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$26.30M 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | $38.67M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |